Revision of EU-GMP Chapter 1 planned with Consultation Phase
Recommendation

25/26 June 2026
PQR, APR, Management Review, Quality Metrics
The EU Commission has published a Stakeholders' Consultation for a revised Chapter 1 of EudraLex Volume 4 - Good Manufacturing Practice Guidelines. The deadline for comments is 3 December 2025.
According to the announcement, the update of Chapter 1 "is necessary to establish efficient regulatory frameworks based on good science and risk management". It has been revised by the EMA GMDP-Inspectors Working Group in co-operation with the Pharmaceutical Inspection Co-operation Scheme (PIC/S).
The planned changes relate to three areas:
Quality Risk Management (QRM)
The revised Chapter 1 primarily reflects the updated ICH guideline on Quality Risk Management, ICH Q9(R1), reinforcing both knowledge management and risk management. Seven new paragraphs/ sections are to be added, incorporating key principles such as:
- Risk-based decision-making throughout the product lifecycle
- A proactive, evidence-based quality culture
- Emphasis on scientific rationale in risk assessment
- An appropriate level of formality in QRM processes
- Consideration of subjectivity in risk assessments and QRM results
- Proactive identification of manufacturing risks to prevent shortages and mitigate supply chain vulnerabilities
Knowledge Management (KM)
Knowledge Management is increasingly recognised as a critical pillar in GMP-regulated areas of the pharmaceutical industry. ICH Q10 (Pharmaceutical Quality System) identifies KM, alongside QRM, as a key "enabler" of an effective quality system. Chapter 1 of the EU-GMP Guidelines already states that a PQS should ensure "product and process knowledge is managed throughout all lifecycle stages," highlighting that KM is not merely a theoretical concept but an expected element of modern GMP operations.
Now, in a new paragraph 1.4(xviii), it is emphasised that Knowledge Management should be applied together with QRM "to provide an early warning system that supports effective oversight and response to evolving quality/manufacturing risks." In addition, a new paragraph 1.13 specifies that "knowledge should be used to make informed decisions, trigger re-evaluations, and stimulate continual improvement."
Product Quality Review (PQR)
The revised chapter also clarifies requirements for the Product Quality Review (PQR), particularly regarding product grouping and situations where only a limited number of batches are manufactured during the review period:
- Trending data from the previous PQR should be included when only a few batches of a product were manufactured in a 12-month review period.
- A minimum content for a PQR is defined for cases where no batches of a product were manufactured during the 12-month review.
- Review timeframes may be adjusted appropriately with adequate justification.
Related GMP News
10.06.2026European QP Association Developments January through April 2026
15.04.2026ICH Q9 Training Package updated
01.04.2026New EMA GMP Guidelines in the next three Years
01.04.2026New EMA Guidance: Risk Management for Elemental Impurities in Veterinary Medicinal Products
18.03.2026Sampling in the Focus of the FDA
11.03.2026EU Pharma Package: Final Texts officially published


